Abstract:Introduction SCBC is an aggressive subtype of bladder cancer with high metastatic potential and few effective therapies. The defining mutations of neuroendocrine cancers include loss-of-function mutations in p53 and Rb and gain-of-function mutations in driver oncogenes (e.g., MYC). We engineered an orthotopic mouse model of SCBC leveraging these defining mutations to investigate the genetic and epigenetic drivers of SCBC. Methods Lentiviral particles carrying Cre recombinase were produced using Lenti-sgNeo#2/Cre. The bladders of genetically engineered Rb1fl/fl Trp53fl/fl MycLSL/LSL (RPM) mice were transduced with Cre recombinase-expressing lentivirus via transurethral catheterization. Mice were monitored by micro-ultrasound (mUS) and bioluminescent imaging and detected tumors were verified by histology. SCBC morphology was confirmed by hematoxylin and eosin (H&E) staining and synaptophysin immunohistochemistry (IHC) by a genitourinary pathologist. Whole transcriptome (RNAseq) analysis was performed to correlate transcriptomic profile of neuroendocrine mouse tumors to a cohort of human SCBC tumors. Candidate driver genes were prioritized and association with prognosis in human tumors was evaluated (TCGA BLCA, n=417). The function of Forkhead box protein family members coordinately up and down regulated in human and murine SCBC was investigated in human urothelial carcinoma and murine syngeneic cell lines. Results Transurethral catheterization successfully transduced the bladder urothelium without evidence of ectopic (non-urothelial) exposure. RPM mice developed SCBC visible on mUS and bioluminescent imaging within 8-10 weeks. As expected in neuroendocrine tumors, mice developed spontaneous visceral and lung metastases. High grade neuroendocrine morphology and NE markers were confirmed on H&E staining and IHC, respectively, by our genitourinary;pathologist. Western blot analysis confirmed Myc expression and suppression of TP53 and RB1. Transcriptomic profiling of both mouse and human SCBC demonstrated concordant gene expression. Gene expression profiling of mouse neuroendocrine bladder tumors and normal bladder showed increased FOXA2 expression in the tumor and high intratumoral FOXA2 protein expression was confirmed on IHC. TCGA-BLCA analysis showed significantly worse overall survival for patients whose bladder tumors overexpressed FOXA2 (p=0.01). Expression of FOXA2 in human urothelial cancer lines harboring p53 and RB mutations led to increased expression of neuroendocrine markers by immunocytochemistry. Conclusions We developed a novel genetically engineered orthotopic murine model of SCBC which is histologically and morphologically similar to human SCBC. Gene expression profiling of neuroendocrine bladder tumors from these mice suggest FOXA2 may play a role in the initiation and development of the neuroendocrine phenotype. Ongoing work seeks to further characterize the role of FOXA2 in neuroendocrine differentiation and identify other genetic and epigenetic markers that may cooperatively contribute to the development of this aggressive variant of bladder cancer.

The Mutational Landscape of MYCN, Lin28b and ALKF1174L Driven Murine Neuroblastoma Mimics Human Disease.

Mouse models of pediatric high-grade gliomas with MYCN amplification reveal intratumoral heterogeneity and lineage signatures

Cytogenomic Characterization of Murine Neuroblastoma Cell Line Neuro-2a and Its Two Derivatives Neuro-2a TR-Alpha and Neuro-2a TR-Beta

A transplantable TH-MYCN transgenic tumor model in C57Bl/6 mice for preclinical immunological studies in neuroblastoma

In Vivo Modeling of Chemoresistant Neuroblastoma Provides New Insights into Chemorefractory Disease and Metastasis

High-Throughput Molecular and Histopathologic Profiling of Tumor Tissue in a Novel Transplantable Model of Murine Neuroblastoma: New Tools for Pediatric Drug Discovery

Convergent genetic aberrations in murine and human T lineage acute lymphoblastic leukemias.

Immune characterization of pre-clinical murine models of neuroblastoma

Single-cell transcriptomics reveals shared immunosuppressive landscapes of mouse and human neuroblastoma

Cross-Species Genomic and Epigenomic Landscape of Retinoblastoma

Preclinical spheroid models identify BMX as a therapeutic target for metastatic MYCN nonamplified neuroblastoma

Abstract 5121: Next-generation immunocompetent and humanized neuroblastoma murine models for the discovery and validation of novel immunotherapies

Conditional c-MYC activation in catecholaminergic cells drives distinct neuroendocrine tumors: neuroblastoma vs somatostatinoma

An integrated single-cell RNA-seq map of human neuroblastoma tumors and preclinical models uncovers divergent mesenchymal-like gene expression programs

The landscape of chromosomal aberrations in breast cancer mouse models reveals driver-specific routes to tumorigenesis

Conditional Activation of c-MYC in Distinct Catecholaminergic Cells Drives Development of Neuroblastoma or Somatostatinoma

If you give a mouse a mutation: comparing the therapeutic utility of renowned mouse models of human cancers

Exome Sequencing Analysis of Murine Medulloblastoma Models Identifies Wdr11 As A Potential Tumor Suppressor in Group 3 Tumors

RNA-Seq Reveals Allele-Specific Expression of Somatic Mutations in Neuroblastoma

A NOVEL ORTHOTOPIC MURINE MODEL OF NEUROENDOCRINE BLADDER CANCER: INSIGHTS INTO THE MOLECULAR DRIVERS OF SMALL CELL BLADDER CANCER (SCBC)

In vivo echographic evidence of tumoral vascularization and microenvironment interactions in metastatic orthotopic human neuroblastoma xenografts